Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA Peptide Vaccine + IL-12 in Metastatic Prostate Cancer
NCT00015977Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Nov 2001
- Primary completion
- Mar 2003
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prostate-specific membrane antigen peptide-pulsed autologous peripheral blood mononuclear cells in prostate cancer (PCa), sponsored by University of Chicago. Primary endpoint: Disease response at 63 days. Started Nov 2001; status: completed.
02
Drugs
prostate-specific membrane antigen peptide-pulsed autologous peripheral blood mononuclear cells
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00015977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00015977.